• 1
    Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg. 1998; 227: 821831.
  • 2
    Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221: 721731; discussion, 731–733.
  • 3
    Levin B, ReMine WH, Hermann RE, et al. Panel: cancer of the pancreas. Am J Surg. 1978; 135: 185191.
  • 4
    Talamini MA, Mosinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg. 1997; 225: 590599.
  • 5
    Ogura Y, Mizumoto R, Isaji S, et al. Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg. 1991; 15: 337343.
  • 6
    Donohue JH, Nagorney DM, Grant CS, et al. Carcinoma of the gallbladder. Does radical resection improve outcome? Arch Surg. 1990; 125: 237241.
  • 7
    Nagorney DM, Donohue JH, Farnell MB, et al. Outcome after curative resection of cholangiocarcinoma. Arch Surg. 1993; 128: 871879.
  • 8
    Bakkevold KE, Arnesjf B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater: results of a controlled, prospective, randomized multicentre study. Eur J Cancer. 1993; 29A: 698703.
  • 9
    Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg. 1994; 168: 361364.
  • 10
    Morrow CE, Sutherland DE, Florack G, et al. Primary gallbladder carcinoma: significance of subserosal lesions and results of aggressive surgical treatment and adjuvant chemotherapy. Surgery. 1983; 94: 709714.
  • 11
    Todoroki T, Iwasaki Y, Orii K, et al. Resection combined with intraoperative radiation (IORT) for stage IV (TNM) gallbladder carcinoma. World J Surg. 1991; 15: 357366.
  • 12
    Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987; 59: 20062010.
  • 13
    Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1991; 21: 11371143.
  • 14
    Mahe M, Romestaing P, Talon B, et al. Radiation therapy in extrahepatic bile duct carcinoma. Radiother Oncol. 1991; 21: 121127.
  • 15
    Rich TA, Evans DB, Curley SA, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol. 1994; 5 (Suppl 3): 7580.
  • 16
    Bosset JF, Mantion G, Gillet M, et al. Primary carcinoma of the gallbladder. Adjuvant postoperative external irradiation. Cancer. 1989; 64: 18431847.
  • 17
    Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120: 899903.
  • 18
    Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation and 5-fluorouracil. Int J Radiat Oncol Biol Phys. 1993; 26: 483489.
  • 19
    Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997; 15: 928937.
  • 20
    Japan Pancreatic Society. Classification of pancreatic carcinoma, 1st English ed., Tokyo: Kanehara, 1996.
  • 21
    Japanese Society of Biliary Surgery. General rules for surgical and pathological study on cancer of the biliary tract, 4th ed. Tokyo: Kanehara, 1997.
  • 22
    Japan Society for Cancer Therapy. Japanese criteria for the evaluation of the direct effects of cancer chemotherapy for solid tumors. J Jpn Soc Cancer Ther. 1986; 21: 943968.
  • 23
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1985; 53: 457481.
  • 24
    Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187220.
  • 25
    Nimura Y, Hayakawa N, Kamiya J, et al. Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology. 1991; 38: 170175.
  • 26
    Kondo S, Nimura Y, Hayakawa N, et al. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg. 2000; 87: 418422.
  • 27
    Sugiura Y, Shima S, Yonekawa H, et al. Hepatopancreatoduodenectomy for carcinoma of the gallbladder invasive to both the liver and the hepatoduodenal ligament [in Japanese with English abstract]. Nippon Geka Gakkai Zasshi. 1987; 88: 13321335.
  • 28
    Hanyu F, Nakamura M, Yoshikawa T. Hepato-ligament pancreatoduodenectomy [in Japanese]. Geka Chiryo. 1988; 59: 1221.
  • 29
    Yasuda H, Takada T, Wada K, et al. A new in-vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg. 1998; 5: 261268.
  • 30
    Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994; 51: 396400.
  • 31
    Takada T, Nimura Y, Kato H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinomas: multicenter randomized trial. Hepatogastroenterology. 1998; 45: 20202026.
  • 32
    Tamura M, Koyama R, Fukuda, M. Clinical trial of the oral carcinostatica, 5-fluorouracil dry syrup, with special reference to plasma and tissue concentrations of the drug [in Japanese]. Jpn J Cancer Chemother. 1975; 2: 297303.
  • 33
    Lee CS. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma. Eur J Surg Oncol. 1997; 23: 233237.
  • 34
    Teh M, Wee A, Raju GC. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer. 1994; 74: 15421545.
  • 35
    Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver. 1996; 16: 99104.
  • 36
    Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995; 22: 774779.
  • 37
    Lee CS, Pirdas A. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Pathology. 1995; 27: 117120.
  • 38
    Lenz HJ, Hayashi K, Salonga D, et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res. 1998; 4: 12431250.
  • 39
    Boku N, Chin K, Hosokawa K, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998; 4: 14691474.
  • 40
    Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55: 14071412.
  • 41
    Etienne MC, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 1995; 13: 16631670.